Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alteplase Manufacturing Processes
NCT04419493Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alteplase in ischemic stroke, acute myocardial infarction (AMI) and pulmonary embolism (PE) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve From 0 to Last Quantifiable Data Point and Maximum Measured Concentration. Started Jun 2020; status: completed.
02
Drugs
alteplase
03
Conditions
ischemic strokeacute myocardial infarction (AMI)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT04419493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419493.